ArticleFrontiers in nutrition2025
A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modern Management of CKM Syndrome: Use of GLP-1 Receptor Agonists in a Multidisciplinary Setting-Expert Group Recommendations from Kuwait.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: An estimated 74.6% of Kuwaiti adults are classified as overweight or obese. As a result, Glucagon-like peptide 1 receptor agonists (GLP-1 RA) injections such as, Semaglutide, Liraglutide, and Tirzepatide have become an increasingly popular intervention for weight loss. However, no research has been published on the use of GLP-1 RA injections in Kuwait. Methods: A cross-sectional study using an online survey was conducted between February and May 2024. Adults in Kuwait who have taken or are currently on GLP-1 RA injections were recruited. The questionnaire collected demographic and clinical data, including weight-loss, side-effects, and quality of life. Results: In this sample of Discussion: This study highlights the varying effectiveness and tolerability of GLP-1 RAs for weight loss in Kuwait, with Tirzepatide showing the highest satisfaction and weight loss. Liraglutide users experienced more anxiety and medication switches, while Semaglutide users had moderate outcomes. Despite their benefits, GLP-1 RAs face challenges in long-term adherence due to side effects and cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.